World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
74
Citations
34596
World Ranking
1532
National Ranking
669

Medicine

D-Index
74
Citations
34785
World Ranking
19265
National Ranking
9596

Overview

Joel E. Gallant is affiliated with the Johns Hopkins University School of Medicine in the United States. Their research primarily focuses on infectious diseases, immunology, and microbiology with a strong emphasis on HIV/AIDS and related complications.

Their main fields of study include:

  • Medicine
  • Immunology and Microbiology

Subfields where they have contributed significantly include:

  • Infectious Diseases
  • Virology
  • Emergency Medicine
  • Epidemiology
  • Neurology

Joel E. Gallant has explored a variety of topics, particularly in relation to HIV/AIDS research and treatment as well as COVID-19 clinical studies. The primary topics of their work are:

  • HIV/AIDS Research and Interventions
  • HIV/AIDS Drug Development and Treatment
  • HIV Research and Treatment
  • HIV-related Health Complications and Treatments
  • HIV, Drug Use, Sexual Risk
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research

Their recent notable papers include:

  • "Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care," 2020, published in Clinical Infectious Diseases
  • "Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial," 2021, published in The Lancet HIV
  • "Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents," 2021, published in AIDS
  • "Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium," 2022, published in HIV Medicine
  • "Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium," 2021, published in The Lancet HIV

Their frequent co-authors consist of:

  • Lene Ryom
  • Kathy Petoumenos
  • Christoph Stephan
  • Antonella Castagna
  • Jens Lundgren

Joel E. Gallant has published multiple works in venues such as:

  • UNC Libraries
  • Clinical Infectious Diseases
  • The Lancet HIV
  • HIV Medicine
  • AIDS

Best Publications

  • Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy

    Diana Finzi;Monika Hermankova;Theodore Pierson;Lucy M. Carruth

  • Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

    Diana Finzi;Joel N Blankson;Janet M Siliciano;Joseph Bernard Margolick

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

    Joel E. Gallant;Schlomo Staszewski;Anton L. Pozniak;Edwin DeJesus

  • Antiretroviral Therapy for the Prevention of HIV-1 Transmission

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

    Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  • Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America

    Judith A. Aberg;Jonathan E. Kaplan;Howard Libman;Patricia Emmanuel

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F. Günthard;Michael S. Saag;Constance A. Benson;Carlos del Rio

  • Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine

    Joel E. Gallant;Richard D. Moore;Richard D. Moore;Douglas D. Richman;Douglas D. Richman;Jeanne Keruly;Jeanne Keruly

  • Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

    Judith A. Aberg;Joel E. Gallant;Khalil G. Ghanem;Patricia Emmanuel

  • Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance

    Ajay K. Sethi;David D. Celentano;Stephen J. Gange;Richard D. Moore;Richard D. Moore

  • Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

    Beatriz Grinsztejn;Mina C. Hosseinipour;Heather J. Ribaudo;Susan Swindells

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

    Paul E. Sax;Edwin DeJesus;Anthony Mills;Andrew Zolopa

  • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

    Unknown

  • Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART

    Richard E. Nettles;Tara L. Kieffer;Tara L. Kieffer;Patty Kwon;Daphne Monie

  • Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

    Jean B. Nachega;Jean Jacques Parienti;Olalekan A. Uthman;Olalekan A. Uthman;Olalekan A. Uthman;Robert Gross

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells

    Justin R. Bailey;Ahmad R. Sedaghat;Tara Kieffer;Timothy Brennan

  • Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

    Joel E. Gallant;Michelle A. Parish;Jeanne C. Keruly;Richard D. Moore

  • Medical Management of HIV Infection

    John G. Bartlett;Joel E. Gallant;Paul A. Pham

  • Executive Summary: Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

    Judith A. Aberg;Joel E. Gallant;Khalil G. Ghanem;Patricia Emmanuel

Frequent Co-Authors

Richard D. Moore
Richard D. Moore Johns Hopkins University
Edwin DeJesus
Edwin DeJesus Hanover University of Applied Sciences and Arts
Robert F. Siliciano
Robert F. Siliciano Johns Hopkins University School of Medicine
Richard E. Chaisson
Richard E. Chaisson Johns Hopkins University
Joseph B. Margolick
Joseph B. Margolick Johns Hopkins University
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Paul A. Volberding
Paul A. Volberding University of California, San Francisco
Eric S. Daar
Eric S. Daar Lundquist Institute
Anton Pozniak
Anton Pozniak London School of Hygiene & Tropical Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to diverse career options, many of which can be explored through related online degrees. For those interested in healthcare and patient support, pursuing programs like a child life specialist offers a fulfilling path focused on helping children cope with medical challenges.

Additionally, some online degrees cater specifically to individuals with unique circumstances. For example, the best degree for felons programs are designed to provide second chances by enabling access to education and career opportunities post-conviction.

Healthcare professionals looking to specialize might consider advanced training through functional medicine NP programs. These programs emphasize holistic approaches to care, complementing microbiology's focus on understanding pathogens and immune responses.

For those interested in the administrative and coding side of healthcare, becoming a CPC (Certified Professional Coder) opens up a career path in medical billing and coding, which plays a crucial role in healthcare systems.

Best Scientists Citing Joel E. Gallant

Trending Scientists